Company intelligence / Profile preview

LangRui Bio

Ownership: Private
Development stage: Other

Overview

LangRui Bio is a clinical-stage biopharmaceutical company based in China, specializing in the development of innovative small molecule drugs and protein degradation therapies. The company leverages its proprietary platform to target high-value pathways in oncology and neurodegenerative diseases, with a particular focus on PROTAC (Proteolysis-targeting chimera) technology. Its lead programs include LR0810, an orally bioavailable estrogen receptor degrader for breast cancer, and LR0705, a CDK4/6 inhibitor. LangRui Bio aims to address unmet medical needs through precision medicine and advanced drug design. The company is backed by prominent venture capital firms and maintains research facilities in Huzhou and Shanghai.

Therapeutic areas: OncologyNeurology
Modalities: Small moleculeProteolysis-targeting chimera therapy
Industry: Biotech

Beyond the preview

Go deeper on LangRui Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LangRui Bio.

Explore the full profile